NCT04234022|Recruiting
Loading search results
Sponsor study identifier
observational
70
1 country
1
Study Start
October 22, 2021
Actual (reported)Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordable drug to study on it's own as well as in combination with other drugs in myeloma and other haematological malignancies. This may lead to potential combination therapies which will be very effective as well as affordable in the future. There is the need to look to see if this drug, Imuthiol and along with complementary drugs lenalidomide (Revlimid) and pomalidomide (Pomalyst) can help in haematological malignancy treatment. In order to do this there is the need to see how the cancer cells respond to the drugs in the laboratory before being able to trial the drug (or combination of drugs) out for treatment. The success of this study may lead to quick translation of Imuthiol into haematological malignancy treatment.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 15, 2020
Actual (reported)January 21, 2020
Actual (reported)October 22, 2021
Actual (reported)December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Imuthiol and zinc efficacy
examine the cyctotoxicity of Imuthiol and zinc in combination with other drugs
7 days
Cell kill and determination of IC50 (inhibitory concentration) and apoptotic pathways involved
Cell kill and determination of IC50 (inhibitory concentration) and apoptotic pathways involved
7 days
samples to be exposed with Zn-DDC (Imuthiol) alone
samples to be exposed with Lenalidomide in combination with Zn-DDC
samples to be exposed with Pomalidomide in combination with Zn-DDC
Zn-DDC added to myeloma samples for culturing
Lanalidomide with Zn-DDC added to myeloma samples for culturing
Up to 60 myeloma bone marrow samples from Myeloma patients and 10 bone marrow samples from other haematological malignancy samples (Acute leukaemia's) at Diagnosis and Relapse will be tested.
The Royal Wolverhampton NHS Trust
Wolverhampton, WV10 0QP, United Kingdom
Supratik Basu
The Royal Wolverhampton NHS Trust
First Submitted
January 15, 2020
First Posted
January 21, 2020
Study Start
October 22, 2021
Actual (reported)Primary Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Bone Pain in Multiple Myeloma- a Translational Study
Lanalidomide with Zn-DDC added to myeloma samples for culturing
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 9, 2026
Record last verified: 2026-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: